Apr 12, 2021 By sarahjibrin Mechanism of Action and Biomarker Strategy for HFB200301, an Anti-TNFR2 Agonist Antibody for the Treatment of Cancer
Apr 12, 2021 By sarahjibrin Discovery and characterization of a novel anti-human CXCR5 antibody for the treatment of B cell lymphomas
Apr 6, 2021 By sarahjibrin HiFiBiO Therapeutics to Present Progress on Four Novel Immunotherapy Programs at AACR 2021
Mar 19, 2021 By sarahjibrin HiFiBiO and Gustave Roussy Researchers Demonstrate the Contribution of Galectin-9 (Gal-9) in Tumor Immune Escape
Mar 8, 2021 By sarahjibrin HiFiBiO Therapeutics CEO Liang Schweizer Interviewed by PharmaBoardRoom and Genialis Podcast
Oct 27, 2020 By sarahjibrin HiFiBiO Therapeutics CEO Liang Schweizer Named one of the World’s Top Female Founders
Oct 26, 2020 By sarahjibrin HiFiBiO Therapeutics Completes First Cohort of a Phase I Study of its SARS-CoV-2 Neutralizing Antibody for the Treatment and Prevention of COVID-19
Sep 24, 2020 By sarahjibrin HiFiBiO Therapeutics CEO Liang Schweizer Receives 2020 Extraordinary Women Advancing Healthcare Award
Sep 17, 2020 By sarahjibrin HiFiBiO Therapeutics Presents Novel Approach to Patient Stratification Demonstrating DIS® Single-Cell Platform at 2020 AACR Tumor Heterogeneity Conference
